A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

NCT00535028 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: AER 001
DRUG: placebo

Sponsor

Aerovance, Inc.

Collaborators

[object Object]